Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Int J Clin Oncol ; 26(7): 1196-1202, 2021 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-33956243

RESUMEN

BACKGROUND: It is well known that chemotherapy for adolescent and young adult (AYA) patients with cancer can reduce fertility regardless of the regimen. A decline in fertility greatly affects the quality of life of cancer survivors in the AYA age group; however, few patients are thought to be receiving fertility preservation measures. METHODS: A questionnaire survey was conducted to assess the current understanding and consideration of fertility among otorhinolaryngologists/head and neck surgeons who treat AYA patients with cancer, and to inform them of the guidelines for fertility preservation. A total of 275 otorhinolaryngologists/head and neck surgeons working at our hospital in Ehime, Japan, six neighboring universities, and their affiliated facilities were included in this study. The questionnaire was mailed and requested to be returned by fax. Twenty questions were asked about respondents' years of experience as physicians, specialties, experience in medical care and chemotherapy for AYA patients with cancer, and knowledge and experience in fertility reduction measures. RESULTS: Although 58.7% of the physicians were aware that cryopreservation of eggs and sperm prior to chemotherapy was recommended, only 7 out of 40 physicians (17.5%) had referred AYA patients with cancer to an appropriate medical facility (department) after obtaining informed consent for chemotherapy. CONCLUSIONS: Although fertility preservation has been discussed at professional conferences and seminars, consideration and actions in the field of otorhinolaryngology/head and neck surgery have not been sufficient. We hope that the results of this survey will help raise awareness of fertility preservation.


Asunto(s)
Preservación de la Fertilidad , Neoplasias , Cirujanos , Adolescente , Conocimientos, Actitudes y Práctica en Salud , Humanos , Japón , Masculino , Neoplasias/tratamiento farmacológico , Calidad de Vida , Encuestas y Cuestionarios , Adulto Joven
2.
Acta Otolaryngol ; 138(7): 664-669, 2018 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-29385889

RESUMEN

OBJECTIVES: Enhanced Recovery After Surgery (ERAS) protocols promote recovery after various invasive surgeries. Likewise, preoperative glucocorticoid administration can reduce complications after some surgeries. However, the effects of ERAS protocols and glucocorticoid administration in patients undergoing major surgery for head and neck cancer have not been well described. The aim of this study was to evaluate the effect of an ERAS protocol with preoperative glucocorticoid administration in major surgery for head and neck cancer. METHODS: This retrospective study included 28 patients who underwent major head and neck surgery with free tissue transfer reconstruction at our institution from September 2016 to May 2017, after implementation of an ERAS protocol with preoperative glucocorticoid administration. Outcomes in that group were compared with those in a control group that underwent surgery from January 2015 to September 2016, before implementation of the protocol. RESULTS: Analysis revealed significantly less body weight fluctuation, lower C-reactive protein levels, higher albumin levels, and lower body temperature in the ERAS group than in the control group postoperatively. CONCLUSIONS: Patients undergoing major surgery for head and neck cancer who were treated with the ERAS protocol and preoperative glucocorticoid administration had evidence of better hemodynamic stability and less inflammatory response than control patients.


Asunto(s)
Dexametasona/administración & dosificación , Glucocorticoides/administración & dosificación , Neoplasias de Cabeza y Cuello/cirugía , Atención Perioperativa/métodos , Complicaciones Posoperatorias/prevención & control , Anciano , Femenino , Colgajos Tisulares Libres , Hemodinámica/efectos de los fármacos , Humanos , Inflamación/prevención & control , Tiempo de Internación , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Trasplante de Tejidos
3.
Toxicology ; 201(1-3): 133-42, 2004 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-15297028

RESUMEN

The object of this study was to investigate the efficacy of (+)-catechin, which was isolated from Actinidia arguta Planch (Actinidiaceae), as a bone marrow cell proliferation-promoting compound against the hematotoxicity of 5-fluorouracil (5-FU) in mice. Intraperitoneally injected (+)-catechin (1 and 10 mg/kg per day) accelerated the recovery of the number of white blood cells (WBC) and platelets (PLT) but did not affect the number of circulating red blood cells (RBC). (+)-Catechin also augmented the number of myelocytes and splenocytes. Dual color flow cytometric analysis revealed that (+)-catechin reversed the reduction of the population of leukocytes (CD11b+ monocytes, Gr-1+ granulocytes and CD3+ T and CD45RA+ B lymphocytes) in whole blood, spleen and bone marrow caused by 5-FU. (+)-Catechin (1 and 10 mg/kg per day) showed remarkable recovery of Gr-1+ cells in all three types of tissues and of CD11b+ cells in the bone marrow cells. These findings suggest that (+)-catechin selectively enhances the recovery of the population of granulocytes reduced by 5-FU in mice.


Asunto(s)
Sangre/efectos de los fármacos , Catequina/uso terapéutico , Fluorouracilo/antagonistas & inhibidores , Inmunosupresores/antagonistas & inhibidores , Animales , Médula Ósea/efectos de los fármacos , Médula Ósea/metabolismo , Femenino , Citometría de Flujo , Fluorouracilo/toxicidad , Inmunosupresores/toxicidad , Inyecciones Intraperitoneales , Ratones , Ratones Endogámicos C57BL , Bazo/efectos de los fármacos , Bazo/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...